MedTrace Logo

Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

NCT01541943 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2015-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of HL-040XC in patients with essential hypertension and hyperlipidemia

Conditions

Interventions

DRUG

Atorvastatin

Once daily, administered orally, 8 week

DRUG

Losartan

Once daily, administered orally, 8 week

DRUG

Placebo

Once daily, administered orally, 8 week

DRUG

HL-040XC

Once daily, administered orally, 8 week

Sponsors & Collaborators

  • HanAll BioPharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chang-Gyu Park, Medicine · Department of Cardiovascular, Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541943 on ClinicalTrials.gov